Free Trial

Chimerix (CMRX) Stock Price, News & Analysis

0.00 (-0.45%)
(As of 05/24/2024 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
271,800 shs
Average Volume
356,043 shs
Market Capitalization
$84.07 million
P/E Ratio
Dividend Yield
Price Target

Chimerix MarketRank™ Stock Analysis

Analyst Rating
3.00 Rating Score
806.2% Upside
$8.50 Price Target
Short Interest
1.71% of Float Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
1.03mentions of Chimerix in the last 14 days
Based on 4 Articles This Week
Insider Trading
Proj. Earnings Growth
From ($0.85) to ($1.03) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.29 out of 5 stars

Medical Sector

151st out of 922 stocks

Pharmaceutical Preparations Industry

60th out of 421 stocks

CMRX stock logo

About Chimerix Stock (NASDAQ:CMRX)

Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors. The company also develops ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for oncology indications; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2. It has license agreement with SymBio Pharmaceuticals to develop and commercialize TEMBEXA for human diseases other than orthopoxviruses, including smallpox. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.

CMRX Stock Price History

CMRX Stock News Headlines

Chimerix Inc.
Chimerix (NASDAQ:CMRX) Downgraded to Sell at
Q1 2024 Chimerix Inc Earnings Call
Chimerix GAAP EPS of -$0.25
Chimerix: Q1 Earnings Snapshot
What Wall Street expects from Chimerix's earnings
CMRX Apr 2024 2.000 call
CMRX Apr 2024 1.000 put
See More Headlines
Receive CMRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Chimerix and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
2 Analysts


Net Income
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
Book Value
$2.17 per share


Free Float
Market Cap
$84.07 million

Social Links

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

CMRX Stock Analysis - Frequently Asked Questions

Should I buy or sell Chimerix stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Chimerix in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CMRX shares.
View CMRX analyst ratings
or view top-rated stocks.

What is Chimerix's stock price target for 2024?

2 brokers have issued 12-month price objectives for Chimerix's stock. Their CMRX share price targets range from $6.00 to $11.00. On average, they anticipate the company's stock price to reach $8.50 in the next year. This suggests a possible upside of 806.2% from the stock's current price.
View analysts price targets for CMRX
or view top-rated stocks among Wall Street analysts.

How have CMRX shares performed in 2024?

Chimerix's stock was trading at $0.9625 at the start of the year. Since then, CMRX stock has decreased by 2.5% and is now trading at $0.9380.
View the best growth stocks for 2024 here

When is Chimerix's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024.
View our CMRX earnings forecast

How were Chimerix's earnings last quarter?

Chimerix, Inc. (NASDAQ:CMRX) issued its earnings results on Wednesday, May, 1st. The biopharmaceutical company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.21) by $0.04. Chimerix had a negative net margin of 25,337.96% and a negative trailing twelve-month return on equity of 41.32%. During the same period in the previous year, the firm posted ($0.24) EPS.

What other stocks do shareholders of Chimerix own?
Who are Chimerix's major shareholders?

Chimerix's stock is owned by many different retail and institutional investors. Top institutional investors include Acadian Asset Management LLC (2.43%), Assenagon Asset Management S.A. (0.51%), Marquette Asset Management LLC (0.13%), Koshinski Asset Management Inc. (0.04%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include David Jakeman, Fred A Middleton, Martha J Demski, Michael T Andriole, Michelle Laspaluto and Robert J Meyer.
View institutional ownership trends

How do I buy shares of Chimerix?

Shares of CMRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CMRX) was last updated on 5/27/2024 by Staff

From Our Partners